BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 1,363 shares of the business's stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $260.00, for a total value of $354,380.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Xiaobin Wu also recently made the following trade(s):
- On Tuesday, June 17th, Xiaobin Wu sold 630 shares of BeOne Medicines stock. The shares were sold at an average price of $250.87, for a total value of $158,048.10.
- On Monday, June 16th, Xiaobin Wu sold 1,543 shares of BeOne Medicines stock. The shares were sold at an average price of $265.52, for a total transaction of $409,697.36.
- On Friday, June 6th, Xiaobin Wu sold 1,934 shares of BeOne Medicines stock. The shares were sold at an average price of $253.15, for a total value of $489,592.10.
- On Tuesday, April 1st, Xiaobin Wu sold 51,921 shares of BeOne Medicines stock. The stock was sold at an average price of $281.40, for a total value of $14,610,569.40.
BeOne Medicines Stock Performance
Shares of NASDAQ ONC traded up $0.33 during mid-day trading on Wednesday, reaching $267.13. The company's stock had a trading volume of 292,986 shares, compared to its average volume of 444,749. The business has a 50-day simple moving average of $246.44. The company has a quick ratio of 1.71, a current ratio of 1.96 and a debt-to-equity ratio of 0.05. The firm has a market cap of $29.28 billion, a PE ratio of -71.81 and a beta of 0.30. BeOne Medicines Ltd. - Sponsored ADR has a 1-year low of $141.31 and a 1-year high of $287.88.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. Analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts have commented on the company. Bank of America raised BeOne Medicines from a "neutral" rating to a "buy" rating and raised their price objective for the company from $207.00 to $320.00 in a report on Monday, March 3rd. Wall Street Zen raised shares of BeOne Medicines from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Sanford C. Bernstein set a $259.00 price objective on shares of BeOne Medicines in a research report on Thursday, March 13th. JPMorgan Chase & Co. lifted their target price on shares of BeOne Medicines from $311.00 to $317.00 and gave the company an "overweight" rating in a research report on Monday, April 21st. Finally, TD Securities restated a "buy" rating and set a $334.00 price target on shares of BeOne Medicines in a research report on Thursday, April 24th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, BeOne Medicines presently has a consensus rating of "Buy" and an average target price of $319.00.
View Our Latest Stock Analysis on ONC
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
